MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with F

Fluvoxamine

Fluvoxamine 50mg tablets

No stability information

Stability notes for Fluvoxamine 50mg tablets

There are no stability notes for this medicine.

Supplier

Faverin 50mg tablets (Viatris UK Healthcare Ltd)

Fluvoxamine 100mg tablets

Use with caution

Stability notes for Fluvoxamine 100mg tablets

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Fluvoxamine 100mg tablets (Wockhardt UK Ltd).

Suppliers

Faverin 100mg tablets (Necessity Supplies Ltd)
Faverin 100mg tablets (Viatris UK Healthcare Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.